A new investigation into the shadowy world of online prescribing has revealed a startling lapse in safety protocols for one of the most sought-after classes of drugs today: glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. These injectable medications, originally developed for type 2 diabetes, have exploded in popularity for their dramatic weight-loss effects, creating unprecedented demand and persistent shortages. Brands like Ozempic, Wegovy, Mounjaro, and Zepbound are household names, but their high cost and limited availability have driven patients to a sprawling ecosystem of direct-to-consumer telemedicine platforms and digital pharmacies. While convenient, a secret shopper study published in JAMA now suggests that many of these vendors are operating with an alarming disregard for basic clinical safeguards, issuing prescriptions based on little more than a quickly filled online form.
Researchers from Yale School of Medicine designed a rigorous cross-sectional study to mimic a patient seeking a GLP-1 RA prescription online. Between October and November 2024, secret shoppers submitted requests to 50 distinct vendors identified through web searches and social media advertisements. The shoppers used standardized profiles that warranted caution — for instance, reporting a body mass index near the threshold for eligibility or describing a history of an eating disorder — to test whether clinicians would probe deeper. The results were sobering. A clear majority of the tested platforms did not require the shopper to speak with a clinician, either by video, phone, or even a real-time chat. Instead, the entire evaluation hinged on an asynchronous questionnaire, a series of checkboxes that could not possibly capture the nuanced social, psychiatric, or family history vital before initiating a drug that fundamentally alters gastric emptying and neural appetite circuits.
The clinical allure of GLP-1 RAs is their multi-faceted mechanism: they bind to receptors in the pancreas, brain, and gastrointestinal tract, stimulating insulin secretion in a glucose-dependent manner, slowing stomach emptying, and signaling satiety to the hypothalamus. Yet this potency also harbors risks. In susceptible individuals, the profound slowing of gastric transit can lead to life-threatening ileus or gastroparesis, while rapid weight loss can unmask dangerous electrolyte disorders. Moreover, sudden, severe caloric restriction can trigger or worsen mood disturbances and disordered eating. A responsible prescription requires a thorough history to screen for personal or family history of medullary thyroid carcinoma or pancreatitis, a discussion of the potential need for gallbladder monitoring, and an assessment of a patient’s psychological readiness — elements virtually impossible to convey in a five-minute online transaction.
The study’s methodology peeled back the curtain on exactly how flimsy these gatekeeping mechanisms can be. Secret shoppers were explicitly instructed not to upload a photograph unless the platform absolutely required it, yet 34% of prescriptions were issued despite the complete absence of any verifying image, a red flag that no clinician visually assessed the patient for signs of severe illness or injection site complications. More tellingly, when looking at prescription timestamps, the researchers discovered that in 22% of cases, the prescription was approved and sent to a pharmacy within 5 minutes of the shopper submitting the questionnaire. Five minutes is less time than it takes to measure blood pressure and calculate a proper risk score, a stark indicator that algorithmic triage, not human judgment, was in the driver’s seat.
Further cracks appeared when the researchers traced the digital identities of the prescribing clinicians. A handful of physicians were found to be authorizing multiple GLP-1 RA prescriptions for the same secret shopper profile across different platforms, suggesting a factory-like model where clinicians sign off on dozens of scripts per hour without any memory of the individual case. The questionnaires themselves, often presented as comprehensive medical evaluations, were revealed on closer inspection to be little more than liability disclaimers, failing to capture critical red flags that even a junior medical student would probe. For instance, a shopper indicating a history of bulimia nervosa — a direct contraindication for a drug that induces rapid, uncontrollable weight loss — was rarely given any follow-up questions or a referral to a mental health provider.
“These findings expose a fundamental flaw in the digital prescription pipeline for highly sought-after medications,” says corresponding author Reshma Ramachandran, an assistant professor at Yale School of Medicine. “We are not opposed to telemedicine innovation, but asynchronous decisions made without clinician interaction, relying on unvalidated patient-reported checkboxes, undo decades of safety frameworks. When a prescription can be issued in five minutes without a photograph, we are essentially giving patients free access to powerful hormonal modulators with no meaningful clinical oversight.” Her team notes that the lack of visual confirmation also means body weight and overall appearance — basic objective data — are never verified, which is particularly dangerous for individuals at the disordered eating threshold where the line between therapeutic use and misuse blurs.
The implications ripple beyond individual patient harm. Pharmaceutical supply chains already strained by unprecedented demand are further pressured when online vendors act as unregulated spigots, often prescribing the highest-cost branded versions. From a regulatory perspective, the study places a harsh spotlight on the ability of state medical boards and the FDA to police these hybrid digital entities that may be registered in one jurisdiction, operate servers in another, and employ clinicians scattered across the globe. The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person evaluation for controlled substances, but GLP-1 RAs sit in a gray zone, not scheduled substances but carrying significant safety profiles that many argue warrant similar safeguards.
While the JAMA investigation does not name specific vendors, the patterns uncovered are widespread, reinforced by the sheer volume of advertising for “weight loss drugs online” that saturates search engines and social platforms. For consumers, the allure of bypassing a long waitlist and an expensive office visit is undeniable. For the medical community, the study serves as a call to action to require synchronous telemedicine visits — even a brief video call — and to enforce better data-sharing between pharmacy benefit managers and state licensing boards to flag outlier prescribers. As GLP-1 RAs progress into new indications for heart failure, sleep apnea, and addiction, the imperative to rebuild a firebreak between a slick web interface and the human body’s complex hormonal circuitry has never been more urgent.
Subject of Research: Online prescribing practices for GLP-1 receptor agonists
Article Title: Assessment of Online Prescribing Practices for Glucagon-Like Peptide-1 Receptor Agonists: A Secret Shopper Study
News Publication Date: 2026
Web References: https://doi.org/10.1001/jama.2026.9131
References: Ramachandran R, et al. Assessment of Online Prescribing Practices for Glucagon-Like Peptide-1 Receptor Agonists: A Secret Shopper Study. JAMA. 2026. doi:10.1001/jama.2026.9131
Image Credits: None
Keywords: GLP-1 receptor agonists, online prescribing, telemedicine regulation, patient safety, secret shopper study, semaglutide, tirzepatide, weight-loss drugs
